^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    NMS-153

    i
    Other names: NMS-153, NMS-01940153E
    Associations

    News

    Trials
    Company:
    Nerviano Medical Sciences
    Drug class:
    TTK inhibitor
    Related drugs:
    Associations

    News

    Trials
    3ms
    Study on Safety and Efficacy of NMS-01940153E in Adult Patients With Unresectable Hepatocellular Carcinoma (HCC) Previously Treated With Systemic Therapy (clinicaltrials.gov)
    P1/2, N=31, Completed, Nerviano Medical Sciences | Active, not recruiting --> Completed | Trial completion date: Mar 2025 --> Aug 2024
    Trial completion • Trial completion date
    |
    NMS-153
    9ms
    Study on Safety and Efficacy of NMS-01940153E in Adult Patients With Unresectable Hepatocellular Carcinoma (HCC) Previously Treated With Systemic Therapy (clinicaltrials.gov)
    P1/2, N=31, Active, not recruiting, Nerviano Medical Sciences | Recruiting --> Active, not recruiting | N=57 --> 31 | Trial completion date: Mar 2026 --> Mar 2025 | Trial primary completion date: Nov 2025 --> Jan 2024
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    NMS-153
    over1year
    Study on Safety and Efficacy of NMS-01940153E in Adult Patients With Unresectable Hepatocellular Carcinoma (HCC) Previously Treated With Systemic Therapy (clinicaltrials.gov)
    P1/2, N=57, Recruiting, Nerviano Medical Sciences | Trial completion date: Mar 2027 --> Mar 2026 | Trial primary completion date: Nov 2026 --> Nov 2025
    Trial completion date • Trial primary completion date
    |
    NMS-153